Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Cited by (1,003)

Items 201–300 of 1,003

1. Active and passive immunotherapy for neurodegenerative disorders
   Brody, David L., Holtzman, David M. · 2008 · Annual Review of Neuroscience
2. Cyclooxygenase‐2‐positive macrophages infiltrate the Alzheimer’s disease brain and damage the blood–brain barrier
   Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., Vinters, H. V. · 2002 · European Journal of Clinical Investigation
3. Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
   Hultqvist, Greta, Syvänen, Stina, Fang, Xiaotian T, Lannfelt, Lars, Sehlin, Dag · 2017 · Theranostics
4. Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
   Bates, K A, Verdile, G, Li, Q-X, Ames, D, Hudson, P, Masters, C L, Martins, R N · 2009 · Molecular Psychiatry
5. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice
   Ana María Martín-Moreno, Begoña Brera, Carlos Spuch, Eva Carro, Luis García‐García, Mercedes Delgado, Miguel A. Pozo, Nadia Giselle Innamorato, Antonio Cuadrado, Maria L. DE CEBALLOS · 2012 · Journal of Neuroinflammation
6. Priority medicines for Europe and the world
   Warren Allan Kaplan, Richard Ogilvie Laing, Bruce Charles Neal · 2004
7. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice
   Malm, Tarja M., Koistinaho, Milla, Pärepalo, Maria, Vatanen, Tero, Ooka, Andreas, Karlsson, Stefan, Koistinaho, Jari · 2005 · Neurobiology of Disease
8. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis
   Makoto Urushitani, Samer Abou Ezzi, Jean‐Pierre Julien · 2007 · Proceedings of the National Academy of Sciences
9. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
   Colin Louis Masters, Roberto Cappai, Kevin Jeffrey Barnham, Victor L. Villemagne · 2006 · Journal of Neurochemistry
10. A Seed for Alzheimer Amyloid in the Brain
    Hideki Hayashi, Nobuyuki Kimura, Haruyasu Yamaguchi, Kazuhiro Hasegawa, Tatsuki Yokoseki, Masao Suzuki Shibata, Naoki Yamamoto, Makoto Michikawa, Yasuhiro Yoshikawa, Keiji Terao et al. · 2004 · Journal of Neuroscience
11. The glymphatic system: implications for drugs for central nervous system diseases
    Terhi Johanna Lohela, Tuomas Olavi Lilius, Maiken Nedergaard · 2022 · Nature Reviews Drug Discovery
12. Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease
    Jankowsky, Joanna L, Slunt, Hilda H, Gonzales, Victoria, Savonenko, Alena V, Wen, Jason C, Jenkins, Nancy A, Copeland, Neal G, Younkin, Linda H, Lester, Henry A, Younkin, Steven G et al. · 2005 · PLoS Medicine
13. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease
    Rogers, Joseph, Lue, Lih-Fen · 2001 · Neurochemistry International
14. Mechanisms of Statin-mediated Inhibition of Small G-protein Function
    Cordle, Andrew, Koenigsknecht-Talboo, Jessica, Wilkinson, Brandy, Limpert, Allison, Landreth, Gary · 2005 · Journal of Biological Chemistry
15. Current and Emerging Drug Treatment Options for Alzheimerʼs Disease
    Nathan Herrmann, Sarah A. Chau, Ida Kircanski, Krista L. Lanctôt · 2011 · Drugs
16. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
    Amy B. Heimberger, Laura E. Crotty Alexander, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, John Howard Sampson · 2003 · PubMed
17. Reduced levels of amyloid β-peptide antibody in Alzheimer disease
    Yansheng Du, Richard C. Dodel, Harald Juergen Hampel, Katharina Büerger, Suizhen Lin, Brian J. Eastwood, Kelly R. Bales, F. Gao, H.–J. Moeller, Wolfgang H. Oertel et al. · 2001 · Neurology
18. Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
    Zetterberg, Henrik · 2012 · Archives of Neurology
19. Serpinopathies and the conformational dementias
    David A. Lomas, Robin W. Carrell · 2002 · Nature Reviews Genetics
20. Genetically engineered mouse models of neurodegenerative diseases
    Philip C. Wong, Huaibin Cai, David Borchelt, Donald L. Price · 2002 · Nature Neuroscience
21. IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor
    Rashid Deane, Abhay P. Sagare, Katie Hamm, Margaret Parisi, Barbra LaRue, Huang Guo, Zhenhua Wu, David M. Holtzman, Berislav V. Zloković · 2005 · Journal of Neuroscience
22. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin
    Milan Fiala, Philip T. Liu, Araceli Espinosa de los Monteros, Mark J. Rosenthal, George W. Bernard, John Matthew Ringman, James William Sayre, Laura Zhang, Justin Zaghi, Sheila Dejbakhsh et al. · 2007 · Proceedings of the National Academy of Sciences
23. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
    Haythum Osama Tayeb, Hyun Duk Yang, Bruce Heimburger Price, Frank I. Tarazi · 2011 · Pharmacology & Therapeutics
24. Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations
    Paul A Yates, Victor L. Villemagne, Kathryn A. Ellis, Patricia M. Desmond, Colin Louis Masters, Christopher Cleon Rowe · 2014 · Frontiers in Neurology
25. Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet
    Lemere, Cynthia A., Beierschmitt, Amy, Iglesias, Melitza, Spooner, Edward T., Bloom, Jeanne K., Leverone, Jodi F., Zheng, Jessica B., Seabrook, Timothy J., Louard, Dora, Li, Diana et al. · 2004 · The American Journal of Pathology
26. Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
    Morgan, D. · 2011 · Journal of Internal Medicine
27. Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation
    Wilcock, Donna M., DiCarlo, Giovanni, Henderson, Debbi, Jackson, Jennifer, Clarke, Keisha, Ugen, Kenneth E., Gordon, Marcia N., Morgan, Dave · 2003 · The Journal of Neuroscience
28. Developing Therapeutic Antibodies for Neurodegenerative Disease
    Y. Joy Yu, Ryan J. Watts · 2013 · Neurotherapeutics
29. Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models
    Scott B. Raymond, Lisa Hsu Treat, Jonathan D. Dewey, Nathan Judson McDannold, Kullervo Hynynen, Brian J. Bacskai · 2008 · PLoS ONE
30. Activation of Microglia Acidifies Lysosomes and Leads to Degradation of Alzheimer Amyloid Fibrils
    Majumdar, Amitabha, Cruz, Dana, Asamoah, Nikiya, Buxbaum, Adina, Sohar, Istvan, Lobel, Peter, Maxfield, Frederick R. · 2007 · Molecular Biology of the Cell
31. Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers
    Nitya Poovaiah, Z. Davoudi, Haibao Peng, Benjamin William Schlichtmann, Surya K. Mallapragada, Balaji Narasimhan, Qun Wang · 2018 · Nanoscale
32. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease
    Ling, Yan, Morgan, Kevin, Kalsheker, Noor · 2003 · The International Journal of Biochemistry & Cell Biology
33. Non‐steroidal anti‐inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action
    Gasparini, Laura, Ongini, Ennio, Wenk, Gary · 2004 · Journal of Neurochemistry
34. Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease
    Ashe, Karen Hsiao · 2001 · Learning & Memory
35. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
    DiCarlo, G · 2001 · Neurobiology of Aging
36. T-helper-1 and T-helper-2 Responses in Psychiatric Disorders
    Markus Schwarz, Sonnig Sue Whei Chiang, Norbert Müller, Manfred Ackenheil · 2001 · Brain Behavior and Immunity
37. Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
    Sadim Jawhar, Oliver Wirths, Thomas A. Bayer · 2011 · Journal of Biological Chemistry
38. Metabolism of amyloid-β peptide and Alzheimer's disease
    Nobuhisa Iwata, Makoto Higuchi, Takaomi C. Saido · 2005 · Pharmacology & Therapeutics
39. A review on advances of treatment modalities for Alzheimer's disease
    Ewen Se Thoe, Ayesha Fauzi, Yin-Quan Tang, Sunita Chamyuang, Adeline Yoke Yin Chia · 2021 · Life Sciences
40. Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide
    Bruno Permanne, Céline Adessi, Gabriela P. Saborı́o, Santiago Fraga, Marie‐José Frossard, Jo Van Dorpe, Ilse Dewachter, William A. Banks, Fred VAN LEUVEN, Claudio A. Soto · 2002 · The FASEB Journal
41. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
    Sahni, Jasjeet Kaur, Doggui, Sihem, Ali, Javed, Baboota, Sanjula, Dao, Lé, Ramassamy, Charles · 2011 · Journal of Controlled Release
42. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
    D’Andrea, Michael R, Cole, Gregory M, Ard, March D · 2004 · Neurobiology of Aging
43. Activation of Complement in the Central Nervous System
    Johan van Beek, Kristina Elward, Philippe Gasque · 2003 · Annals of the New York Academy of Sciences
44. Immunotherapeutic Approaches to Alzheimer's Disease
    Alon Monsonego, Howard L. Weiner · 2003 · Science
45. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
    Farfara, D., Lifshitz, V., Frenkel, D. · 2008 · Journal of Cellular and Molecular Medicine
46. The immunology of neurodegeneration
    Eva Czirr, Tony Wyss‐Coray · 2012 · Journal of Clinical Investigation
47. Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
    Kevin Mullane, Michael J. Williams · 2012 · Biochemical Pharmacology
48. Mouse Models of Alzheimer’s Disease
    Yokoyama, Miyabishara, Kobayashi, Honoka, Tatsumi, Lisa, Tomita, Taisuke · 2022 · Frontiers in Molecular Neuroscience
49. Transgenic models of Alzheimer’s disease: Learning from animals
    Tara L. Spires‐Jones, Bradley T. Hyman · 2005 · NeuroRx
50. IFN-γ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice
    Chakrabarty, Paramita, Ceballos-Diaz, Carolina, Beccard, Amanda, Janus, Christopher, Dickson, Dennis, Golde, Todd E, Das, Pritam · 2010 · The Journal of Immunology
51. The role of cell-derived oligomers of Aβ in Alzheimer's disease and avenues for therapeutic intervention
    D.M. Walsh, I. Klyubin, G.M. Shankar, Matthew Townsend, Julia V. Fadeeva, Vicki Betts, Marcia Berman Podlisny, James P. Cleary, Karen H. Ashe, Michael J. Rowan et al. · 2005 · Biochemical Society Transactions
52. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease
    Takashi Mori, Naoki Koyama, Gary W. Arendash, Yuko Horikoshi‐Sakuraba, Jun Tan, Terrence Town · 2009 · Glia
53. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay
    Volker Heiser, Sabine Engemann, Wolfgang Bröcker, Ilona Dunkel, Annett Boeddrich, Stephanie Waelter, Eddi Nordhoff, Rudi Lurz, Nancy Schugardt, Susanne Rautenberg et al. · 2002 · Proceedings of the National Academy of Sciences
54. Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease
    Dennis J. Selkoe · 2002 · Journal of Clinical Investigation
55. Alzheimer's disease drug development and the problem of the blood‐brain barrier
    William M. Pardridge · 2009 · Alzheimer s & Dementia
56. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
    Dennis J. Selkoe · 2001 · Proceedings of the National Academy of Sciences
57. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis
    Jeffrey M. Redwine, Barry E. Kosofsky, Russell E. Jacobs, Dora Games, John F. Reilly, John H. Morrison, Warren G. Young, Floyd E. Bloom · 2003 · Proceedings of the National Academy of Sciences
58. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration
    Wilcock, Donna M, Munireddy, Sanjay K, Rosenthal, Arnon, Ugen, Kenneth E, Gordon, Marcia N, Morgan, Dave · 2004 · Neurobiology of Disease
59. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
    Marc E. Weksler, Norman R. Relkin, Rimma Turkenich, Susan LaRusse, Ling Zhou, Paul Szabo · 2002 · Experimental Gerontology
60. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
    Paul S. S. Aisen, Daniel Saumier, Richard Briand, J. Laurin, Francine Gervais, Patrick J. Tremblay, D. Garceau · 2006 · Neurology
61. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
    Sara Snogerup Linse, Tom Scheidt, Katja Bernfur, Michele Vendruscolo, Christopher Martin Dobson, Samuel I. A. Cohen, Eimantas Šileikis, Martin Lundqvist, Fang Qian, Tiernan T. O’Malley et al. · 2020 · Nature Structural & Molecular Biology
62. Tumor necrosis factor α Inhibition for Alzheimer’s Disease
    Chang, Rudy, Yee, Kei-Lwun, Sumbria, Rachita K · 2017 · Journal of Central Nervous System Disease
63. Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
    William M. Pardridge · 2020 · Pharmaceuticals
64. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice
    Brendza, Robert P., Bacskai, Brian J., Cirrito, John R., Simmons, Kelly A., Skoch, Jesse M., Klunk, William E., Mathis, Chester A., Bales, Kelly R., Paul, Steven M., Hyman, Bradley T. et al. · 2005 · Journal of Clinical Investigation
65. Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier
    Isabelle St‐Amour, Isabelle Paré, Waël Alata, Katherine Coulombe, Cassandra Ringuette Goulet, Janelle Drouin‐Ouellet, Milène Vandal, Denis Soulet, Renée Bazin, Frédéric Calon · 2013 · Journal of Cerebral Blood Flow & Metabolism
66. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
    Eric Siemers, Stuart W. Friedrich, Robert A. Dean, Celedon Gonzales, Martin Rhys Farlow, Steven M. Paul, Ronald Bradley Demattos · 2010 · Clinical Neuropharmacology
67. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
    Xiang, Xianyuan, Werner, Georg, Bohrmann, Bernd, Liesz, Arthur, Mazaheri, Fargol, Capell, Anja, Feederle, Regina, Knuesel, Irene, Kleinberger, Gernot, Haass, Christian · 2016 · EMBO Molecular Medicine
68. The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
    Christoph Wießner, Karl‐Heinz Wiederhold, Alain C. Tissot, P. Frey, S. Danner, Laura H. Jacobson, Gary T. Jennings, Rainer M. Lüönd, Rainer Ortmann, Julia Reichwald et al. · 2011 · Journal of Neuroscience
69. Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
    Rommy von Bernhardi M., Jaime L. Eugenín · 2011 · Antioxidants and Redox Signaling
70. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
    Goure, William F, Krafft, Grant A, Jerecic, Jasna, Hefti, Franz · 2014 · Alzheimer's Research & Therapy
71. Immunization Delays the Onset of Prion Disease in Mice
    Einar M. Sigurdsson, David R. Brown, Maki Daniels, Richard J. Kascsak, Regina Kascsak, Richard Carp, Harry C. Meeker, Blas Frangione, Thomas Wısnıewskı · 2002 · American Journal Of Pathology
72. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model
    Lee, Jong Kil, Jin, Hee Kyung, Bae, Jae-sung · 2009 · Neuroscience Letters
73. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS
    François Gros‐Louis, Geneviève Soucy, Roxanne Larivière, Jean‐Pierre Julien · 2010 · Journal of Neurochemistry
74. Therapeutic strategies for Alzheimer's disease
    Michael S. Wolfe · 2002 · Nature Reviews Drug Discovery
75. Can Dementia Be Prevented? Brain Aging in a Population-Based Context
    Mary N. Haan, Robert B. Wallace · 2004 · Annual Review of Public Health
76. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration
    Riddhi Solanki, Anjali A. Karande, Prathibha Ranganathan · 2023 · Frontiers in Neurology
77. Targeting microglia for the treatment of Alzheimer’s Disease
    Wes, Paul D., Sayed, Faten A., Bard, Frédérique, Gan, Li · 2016 · Glia
78. Anti‐tau antibody reduces insoluble tau and decreases brain atrophy
    Yanamandra, Kiran, Jiang, Hong, Mahan, Thomas E., Maloney, Susan E., Wozniak, David F., Diamond, Marc I., Holtzman, David M. · 2015 · Annals of Clinical and Translational Neurology
79. Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
    Banks, William A. · 2012 · Advanced Drug Delivery Reviews
80. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease
    Shukla, Varsha, Skuntz, Susan, Pant, Harish C. · 2012 · Archives of Medical Research
81. Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease
    William A. Banks, Brie Terrell, Susan A. Farr, Sandra M. Robinson, Naoko Nonaka, John Edward Morley · 2002 · Peptides
82. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia
    Fu, Hongjun, Liu, Bin, Frost, Jeffrey L., Hong, Soyon, Jin, Ming, Ostaszewski, Beth, Shankar, Ganesh M., Costantino, Isabel M., Carroll, Michael C., Mayadas, Tanya N. et al. · 2012 · Glia
83. Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide
    Michael G. Agadjanyan, Anahit Ghochikyan, Irina Petrushina, Vitaly Vasilevko, Nina Movsesyan, Mikayel Mkrtichyan, Tommy Saing, David H. Cribbs · 2005 · The Journal of Immunology
84. Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP–Induced β-Cell Apoptosis in h-IAPP Transgenic Mice
    Chia‐Yu Lin, Tatyana Gurlo, Rakez Kayed, Alexandra E. Butler, Leena Haataja, Charles G. Glabe, Peter C. Butler · 2007 · Diabetes
85. Amyloid-Peptide Vaccinations Reduce β-Amyloid Plaques but Exacerbate Vascular Deposition and Inflammation in the Retina of Alzheimer’s Transgenic Mice
    Liu, Bingqian, Rasool, Suhail, Yang, Zhikuan, Glabe, Charles G., Schreiber, Steven S., Ge, Jian, Tan, Zhiqun · 2009 · The American Journal of Pathology
86. Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients
    Laura Zhang, Milan Fiala, John Richard Cashman, James William Sayre, Araceli Espinosa de los Monteros, Michelle Mahanian, Justin Zaghi, Vladimir Badmaev, Michael C. Graves, George W. Bernard et al. · 2006 · Journal of Alzheimer s Disease
87. Knife‐edge scanning microscopy for imaging and reconstruction of three‐dimensional anatomical structures of the mouse brain
    David Matthew Mayerich, Louise C. Abbott, Bruce H. McCormick · 2008 · Journal of Microscopy
88. Transgenic mouse models of alzheimer disease: Developing a better model as a tool for therapeutic interventions.
    Kitazawa, Masashi, Medeiros, Rodrigo, M. LaFerla, Frank · 2012 · Current Pharmaceutical Design
89. Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
    Rogers, Joseph, Li, Rena, Mastroeni, Diego, Grover, Andrew, Leonard, Brian, Ahern, Geoffrey, Cao, Phillip, Kolody, Heather, Vedders, Linda, Kolb, William P. et al. · 2006 · Neurobiology of Aging
90. Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics
    David Morgan, Marcia N. Gordon, Jun Tan, Donna M. Wilcock, Amyn M. Rojiani · 2005 · Journal of Neuropathology & Experimental Neurology
91. Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer’s Disease?
    Antoine Louveau, Sandro Dá Mesquita, Jonathan Kipnis · 2016 · Neuron
92. Transgenic mouse models of Alzheimer's disease
    Christopher Janus, David A. Westaway · 2001 · Physiology & Behavior
93. β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
    Buttini, Manuel, Masliah, Eliezer, Barbour, Robin, Grajeda, Henry, Motter, Ruth, Johnson-Wood, Kelly, Khan, Karen, Seubert, Peter, Freedman, Stephen, Schenk, Dale et al. · 2005 · The Journal of Neuroscience
94. Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
    Masashi Kitazawa, Tritia R. Yamasaki, Frank M. LaFerla · 2004 · Annals of the New York Academy of Sciences
95. Protein fibrillation and nanoparticle interactions: opportunities and challenges
    Morteza Mahmoudi, Hamid Reza Kalhor, Sophie Laurent, Iseult Lynch · 2013 · Nanoscale
96. Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
    Joseph D. Romano, Nicholas P. Tatonetti · 2019 · Frontiers in Genetics
97. Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
    Takata, Kazuyuki, Kitamura, Yoshihisa, Saeki, Mana, Terada, Maki, Kagitani, Sachiko, Kitamura, Risa, Fujikawa, Yasuhiro, Maelicke, Alfred, Tomimoto, Hidekazu, Taniguchi, Takashi et al. · 2010 · Journal of Biological Chemistry
98. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
    Andreas Muhs, David T. Hickman, Maria Pihlgren, Nathalie Chuard, Valérie Giriens, Carine Meerschman, Ingrid Van der Auwera, Fred VAN LEUVEN, Masae Sugawara, Marie-Catherine Weingertner et al. · 2007 · Proceedings of the National Academy of Sciences
99. A Decade of Tau Transgenic Animal Models and Beyond
    Jürgen Götz, Natasha A. Deters, Amy Doldissen, Laita Bokhari, Yazi Diana Ke, Andreas Wiesner, Nicole Schönrock, Lars Matthias Ittner · 2007 · Brain Pathology
100. Microglia Activation and Anti-inflammatory Regulation in Alzheimer’s Disease
     Lih‐Fen Lue, Yu‐Min Kuo, Thomas G. Beach, Douglas G. Walker · 2010 · Molecular Neurobiology